- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
JB Chemicals, Cipla dragged to court for alleged infringement of Vifor FCM patent
Overview
Cipla Ltd and J B Chemicals and Pharmaceuticals have been embroiled in a court case as Swiss drug firm Vifor International moves Delhi High Court seeking permanent injunction restraining the two drug majors from alleged infringement of the patent of its iron carbohydrate complex drug ferric carboxymaltose (FCM).
Vifor International received the patent for manufacturing of water-soluble iron carbohydrate complex, designated as ferric carboxymaltose or iron carboxymaltose, which is used for the intravenous treatment of iron deficiency and iron deficiency anaemia when oral iron preparations are ineffective or cannot be used, on June 25, 2008 with a priority date of October 23, 2002 and the term of the patent expires on October 20, 2023.
For more details, check out the link given below:
Cipla, JB Chemicals Dragged To Court For Alleged Infringement Of Vifor FCM Patent